We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
IMMUNOPHENOTYPIC CHARACTERIZATION OF RICHTER SYNDROME DIFFUSE LARGE B‐CELL LYMPHOMA TYPE AND COMPARISON WITH THE ORIGINAL CHRONIC LYMPHOCYTIC LEUKEMIA.
- Authors
Martin‐Moro, F.; Marquet‐Palomanes, J.; Piris‐Villaespesa, M.; Garcia‐Cosio, M.; Ballester, R.; Rodriguez‐Martin, E.; Moreno‐Jimenez, G.; Garcia‐Vela, J. A.; Roldan, E.; Lopez‐Jimenez, F. J.
- Abstract
Treatment for the DLBCL-RS was initiated in 8/12 cases, being 92% death at data cut-off date (median follow-up 6.5 months from DLBCL-RS diagnosis, IQR 2.4-9.7). Three cases were concomitantly diagnosed with CLL and DLBCL-RS; the median time of transformation in the remaining 9/12 was 76 months (IQR 51-112), and all of them had received at least 1 therapeutic line for the CLL (median 2). B Introduction: b Biological mechanisms undergoing Richter Syndrome diffuse large B-cell lymphoma type (DLBCL-RS) from a previous chronic lymphocytic leukemia (CLL) arouse a great scientific interest, but the pattern of markers expressed in DLBCL-RS cases has been scarcely studied.
- Subjects
RICHTER syndrome; CHRONIC lymphocytic leukemia; DIFFUSE large B-cell lymphomas; CHRONIC leukemia
- Publication
Hematological Oncology, 2023, Vol 41, p645
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3165_495